Stockreport

Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor

AEVI GENOMIC MEDICINE INC  (GNMX) 
Last aevi genomic medicine inc earnings: 11/14 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: aevigenomics.com
PDF PHILADELPHIA, July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OS [Read more]